Amylin has announced positive results from a 28-week dose-ranging study of pramlintide/metreleptin, a combination treatment comprising pramlintide and metreleptin in overweight and obese patients. This phase-II study successfully
AstraZeneca has terminated the license agreement with MAP Pharmaceuticals, regarding Unit Dose Budesonide (UDB). UDB, an investigational treatment for paediatric asthma, was the subject of an initial phase-III
Chattem has reported an increase in total revenue by 4.4% to $121.8 million for the second quarter of fiscal 2009, as compared to $116.7 million in the prior
Bioheart has announced successful completion of series D financing, that commenced on October 1, 2008, and through July 7, 2009. Bioheart has raised an amount of $2.8 million
Shanghai ChemPartner (ChemPartner) has expanded its integrated drug discovery research collaboration with Agios. ChemPartner would provide integrated services in the areas of protein science, HTS, in-vitro enzyme assay,
AngioChem’s first patent has been granted by the US Patent and Trademark office. US Patent Number 7557182 is entitled to Aprotinin polypeptides for transporting a compound across the
BioAlliance has received European approval for embossing Loramyc mucoadhesive buccal tablet, for the treatment of oropharyngeal candidiasis. The embossing process has been approved under the Mutual Recognition Procedure.
Stem Cell has issued two patents in India, Indian Patent No. 229684 entitled – Combined Regulation of Neural Cell Production, and Indian Patent No. 229924 entitled – A
Novavax and Cadila Pharmaceuticals have launched a joint venture in India, under the agreement signed between the two companies in March 2009. This joint venture CPL Biologicals, would
Highlights include 11% sequential revenue increase over Q1 2009 and 8% sensor growth compared with Q2 2008, the third consecutive quarter of year over year sensor growth. Sales
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.